文献速递心脑血管急症消化、代谢与肾脏急症

钠-葡萄糖协同转运蛋白2抑制剂的使用与主要心血管事件及心力衰竭风险:斯堪的纳维亚注册登记队列研究

Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study.
PubMed 文献 · BMJ · 2019-08-29
一句话结论在斯堪的纳维亚大型队列中,SGLT2抑制剂与DPP4抑制剂相比与心力衰竭和全因死亡风险降低相关,但在主要意向治疗分析中与主要心血管事件无关。

该研究基于丹麦、挪威和瑞典全国注册登记数据,采用活性对照新使用者设计,纳入SGLT2抑制剂新使用者与DPP4抑制剂新使用者各20983例,按年龄、性别、主要心血管疾病史和倾向评分匹配。主要终点为主要心血管事件(心肌梗死、卒中和心血管死亡的复合终点)和心力衰竭(因心力衰竭住院或心力衰竭死亡)。在意向治疗分析中,SGLT2抑制剂与DPP4抑制剂相比,主要心血管事件风险无显著差异(HR 0.94,95%CI 0.84-1.06),但心力衰竭风险降低(HR 0.66,95%CI 0.53-0.81)。在按治疗分析中,心力衰竭(HR 0.55,95%CI 0.42-0.73)、主要心血管事件(HR 0.84,95%CI 0.72-0.98)和全因死亡(HR 0.75,95%CI 0.61-0.91)风险均降低。这些数据有助于了解SGLT2抑制剂在常规临床实践中的心血管有效性。

要点

  • 在匹配的SGLT2抑制剂与DPP4抑制剂新使用者中,SGLT2抑制剂与心力衰竭风险降低相关(HR 0.66,95%CI 0.53-0.81)。
  • 意向治疗分析中,SGLT2抑制剂与主要心血管事件风险无显著差异(HR 0.94,95%CI 0.84-1.06)。
  • 按治疗分析中,SGLT2抑制剂与主要心血管事件风险降低相关(HR 0.84,95%CI 0.72-0.98),主要由心血管死亡成分驱动。
  • 按治疗分析中,SGLT2抑制剂与全因死亡风险降低相关(HR 0.75,95%CI 0.61-0.91)。
  • 亚组分析显示,无论有无主要心血管疾病史或心力衰竭史,风险比一致。

适用人群与场景

  • 年龄35-84岁的新使用SGLT2抑制剂或DPP4抑制剂的患者,来自丹麦、挪威和瑞典全国注册登记,2013年4月至2016年12月。
  • 按年龄、性别、主要心血管疾病史和倾向评分匹配。
  • 研究队列平均年龄61岁,60%为男性,19%有主要心血管疾病史。

研究设计与关键结果

  • 研究设计为基于全国注册登记的队列研究,采用活性对照新使用者设计,SGLT2抑制剂组和DPP4抑制剂组各20983例。
  • SGLT2抑制剂组总随访27416人年,其中达格列净占22627人年(83%),恩格列净占4521人年(16%),卡格列净占268人年(1%)。
  • 随访期间,SGLT2抑制剂组467例发生主要心血管事件(发生率17.0事件/1000人年),DPP4抑制剂组662例(18.0事件/1000人年);SGLT2抑制剂组130例发生心力衰竭事件(4.7事件/1000人年),DPP4抑制剂组265例(7.1事件/1000人年)。
  • 主要分析(意向治疗)中,SGLT2抑制剂与DPP4抑制剂相比,主要心血管事件HR 0.94(95%CI 0.84-1.06),心力衰竭HR 0.66(95%CI 0.53-0.81)。
  • 次要终点HR:心肌梗死0.99(95%CI 0.85-1.17),卒中0.94(95%CI 0.77-1.15),心血管死亡0.84(95%CI 0.65-1.08),全因死亡0.80(95%CI 0.69-0.92)。
  • 按治疗分析中,主要心血管事件HR 0.84(95%CI 0.72-0.98),心力衰竭HR 0.55(95%CI 0.42-0.73),心肌梗死HR 0.93(95%CI 0.76-1.14),卒中HR 0.83(95%CI 0.64-1.07),心血管死亡HR 0.67(95%CI 0.49-0.93),全因死亡HR 0.75(95%CI 0.61-0.91)。

证据类型、等级与局限

  • 证据类型:基于全国注册登记的队列研究,采用活性对照新使用者设计。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在常规临床实践中,SGLT2抑制剂与DPP4抑制剂相比可能与心力衰竭和全因死亡风险降低相关,但主要心血管事件风险在主要意向治疗分析中无显著差异。
  • 按治疗分析中观察到主要心血管事件风险降低,主要由心血管死亡成分驱动。
  • 这些数据有助于患者、医生和管理部门了解SGLT2抑制剂在常规临床实践中的心血管有效性。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To investigate the cardiovascular effectiveness of sodium glucose cotransporter 2 (SGLT2) inhibitors in routine clinical practice.

DESIGN: Cohort study using data from nationwide registers and an active-comparator new-user design.

SETTING: Denmark, Norway, and Sweden, from April 2013 to December 2016.

PARTICIPANTS: 20 983 new users of SGLT2 inhibitors and 20 983 new users of dipeptidyl peptidase 4 (DPP4) inhibitors, aged 35-84, matched by age, sex, history of major cardiovascular disease, and propensity score.

MAIN OUTCOME MEASURES: Primary outcomes were major cardiovascular events (composite of myocardial infarction, stroke, and cardiovascular death) and heart failure (hospital admission for heart failure or death due to heart failure). Secondary outcomes were the individual components of the cardiovascular composite and any cause death. In the primary analyses, patients were defined as exposed from treatment start throughout follow-up (analogous to intention to treat); additional analyses were conducted with an as-treated exposure definition. Cox regression was used to estimate hazard ratios.

RESULTS: Mean age of the study cohort was 61 years, 60% were men, and 19% had a history of major cardiovascular disease. Of the total 27 416 person years of follow-up in the SGLT2 inhibitor group, 22 627 (83%) was among patients who initiated dapagliflozin, 4521 (16%) among those who initiated empagliflozin, and 268 (1%) among those who initiated canagliflozin. During follow-up, 467 SGLT2 inhibitor users (incidence rate 17.0 events per 1000 person years) and 662 DPP4 inhibitor users (18.0) had a major cardiovascular event, whereas 130 (4.7) and 265 (7.1) had a heart failure event, respectively. Hazard ratios were 0.94 (95% confidence interval 0.84 to 1.06) for major cardiovascular events and 0.66 (0.53 to 0.81) for heart failure. Hazard ratios were consistent among subgroups of patients with and without history of major cardiovascular disease and with and without history of heart failure. Hazard ratios for secondary outcomes, comparing SGLT2 inhibitors with DPP4 inhibitors, were 0.99 (0.85 to 1.17) for myocardial infarction, 0.94 (0.77 to 1.15) for stroke, 0.84 (0.65 to 1.08) for cardiovascular death, and 0.80 (0.69 to 0.92) for any cause death. In the as-treated analyses, hazard ratios were 0.84 (0.72 to 0.98) for major cardiovascular events, 0.55 (0.42 to 0.73) for heart failure, 0.93 (0.76 to 1.14) for myocardial infarction, 0.83 (0.64 to 1.07) for stroke, 0.67 (0.49 to 0.93) for cardiovascular death, and 0.75 (0.61 to 0.91) for any cause death.

CONCLUSIONS: In this large Scandinavian cohort, SGLT2 inhibitor use compared with DPP4 inhibitor use was associated with reduced risk of heart failure and any cause death, but not with major cardiovascular events in the primary intention-to-treat analysis. In the additional as-treated analyses, the magnitude of the association with heart failure and any cause death became larger, and a reduced risk of major cardiovascular events that was largely driven by the cardiovascular death component was observed. These data help inform patients, practitioners, and authorities regarding the cardiovascular effectiveness of SGLT2 inhibitors in routine clinical practice.

来源:BMJ,查看原文。版权归原作者所有。

参考来源

  1. Pasternak B, Ueda P, Eliasson B, et al. Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study. BMJ. 2019. PMID: 31467044. doi:10.1136/bmj.l4772

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。